Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 15/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020210 | 0.88 | DRD4 (0.55) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3686563 | 0.88 | DRD4 (0.55) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4021469 | 0.80 | PKM (0.49) | CCR2KCNH2 | |
| Oxalic Acid SCHEMBL17891318 | 0.78 | DRD4 (0.60) | DRD4CCR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4496185 | 0.77 | CCR3 (0.68) | DRD4CCR3KCNH2CYP1A2CYP3A4 | |
| SCHEMBL3922376 | 0.77 | CCR3 (0.68) | DRD4CCR3KCNH2CYP1A2CYP3A4 | |
| SCHEMBL4496189 | 0.77 | DRD4 (0.51) | DRD4CCR3KCNH2S1PR5KDM4E | |
| SCHEMBL1810573 | 0.76 | CCR3 (0.67) | DRD4CCR3CCR2KCNH2CYP1A2 | |
| SCHEMBL1810572 | 0.76 | CCR3 (0.67) | DRD4CCR3CCR2KCNH2CYP1A2 | |
| SCHEMBL30211803 | 0.76 | CCR3 (0.67) | DRD4CCR3CCR2KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-7732461-B2 | (4S)-4-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-3-fluoro-4-hydroxy-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-7-one, used in the treatment of bacterial infections caused by a wide range of organisms including both gramnegative and grampositive bacteria | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | NRDC, NACA, ASNS | DRD4 1282/4885CCR3 3580/4885CCR2 2135/4885 |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | DRD4 624/4885CCR3 4646/4885CCR2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.